LUCID DIAGNOSTICS INC (LUCD) Stock Fundamental Analysis
NASDAQ:LUCD - Nasdaq - US54948X1090 - Common Stock - Currency: USD
Taking everything into account, LUCD scores 1 out of 10 in our fundamental rating. LUCD was compared to 187 industry peers in the Health Care Equipment & Supplies industry. LUCD has a bad profitability rating. Also its financial health evaluation is rather negative. LUCD is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year LUCD has reported negative net income.
In the past year LUCD has reported a negative cash flow from operations.
In the past 5 years LUCD always reported negative net income.
In the past 5 years LUCD always reported negative operating cash flow.
1.2 Ratios
LUCD has a worse Return On Assets (-216.30%) than 93.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -216.3% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-179.51%
ROA(5y)-192.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LUCD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
LUCD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, LUCD has more shares outstanding
LUCD has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, LUCD has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -13.31, we must say that LUCD is in the distress zone and has some risk of bankruptcy.
LUCD has a Altman-Z score of -13.31. This is amonst the worse of the industry: LUCD underperforms 85.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -13.31 |
ROIC/WACCN/A
WACC8.33%
2.3 Liquidity
LUCD has a Current Ratio of 0.75. This is a bad value and indicates that LUCD is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.75, LUCD is not doing good in the industry: 92.51% of the companies in the same industry are doing better.
A Quick Ratio of 0.74 indicates that LUCD may have some problems paying its short term obligations.
LUCD has a worse Quick ratio (0.74) than 89.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.75 | ||
| Quick Ratio | 0.74 |
3. Growth
3.1 Past
LUCD shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.28%.
LUCD shows a strong growth in Revenue. In the last year, the Revenue has grown by 39.99%.
The Revenue has been growing by 105.61% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)3.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30%
Revenue 1Y (TTM)39.99%
Revenue growth 3Y105.61%
Revenue growth 5YN/A
Sales Q2Q%-17.28%
3.2 Future
LUCD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.09% yearly.
LUCD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 87.84% yearly.
EPS Next Y26.34%
EPS Next 2Y29.28%
EPS Next 3Y20.78%
EPS Next 5Y12.09%
Revenue Next Year39.76%
Revenue Next 2Y104.15%
Revenue Next 3Y112.24%
Revenue Next 5Y87.84%
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
LUCD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LUCD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as LUCD's earnings are expected to grow with 20.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.28%
EPS Next 3Y20.78%
5. Dividend
5.1 Amount
No dividends for LUCD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.14
-0.04 (-3.39%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners9.78%
Inst Owner Change0%
Ins Owners5.61%
Ins Owner Change6.95%
Market Cap123.34M
Analysts83.33
Price Target3.87 (239.47%)
Short Float %2.34%
Short Ratio1.32
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-107.57%
Min EPS beat(2)-222.25%
Max EPS beat(2)7.12%
EPS beat(4)1
Avg EPS beat(4)-57.26%
Min EPS beat(4)-222.25%
Max EPS beat(4)7.12%
EPS beat(8)3
Avg EPS beat(8)-32.88%
EPS beat(12)5
Avg EPS beat(12)-20.28%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-27.13%
Min Revenue beat(2)-36.75%
Max Revenue beat(2)-17.51%
Revenue beat(4)1
Avg Revenue beat(4)-18.86%
Min Revenue beat(4)-36.75%
Max Revenue beat(4)0.77%
Revenue beat(8)1
Avg Revenue beat(8)-20.24%
Revenue beat(12)2
Avg Revenue beat(12)-25.84%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.11%
PT rev (3m)3.41%
EPS NQ rev (1m)20%
EPS NQ rev (3m)27.33%
EPS NY rev (1m)-28.35%
EPS NY rev (3m)-11.39%
Revenue NQ rev (1m)-16.49%
Revenue NQ rev (3m)-34.37%
Revenue NY rev (1m)-21.81%
Revenue NY rev (3m)-32.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 29.56 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.18
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS0.04
BVpS-0.05
TBVpS-0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -216.3% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-179.51%
ROA(5y)-192.84%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.13
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 79.14% | ||
| Cap/Sales | 16.82% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.75 | ||
| Quick Ratio | 0.74 | ||
| Altman-Z | -13.31 |
F-Score4
WACC8.33%
ROIC/WACCN/A
Cap/Depr(3y)37.04%
Cap/Depr(5y)N/A
Cap/Sales(3y)87.81%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30%
EPS Next Y26.34%
EPS Next 2Y29.28%
EPS Next 3Y20.78%
EPS Next 5Y12.09%
Revenue 1Y (TTM)39.99%
Revenue growth 3Y105.61%
Revenue growth 5YN/A
Sales Q2Q%-17.28%
Revenue Next Year39.76%
Revenue Next 2Y104.15%
Revenue Next 3Y112.24%
Revenue Next 5Y87.84%
EBIT growth 1Y-6.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.14%
EBIT Next 3Y3.6%
EBIT Next 5Y7.06%
FCF growth 1Y-40.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-42.1%
OCF growth 3YN/A
OCF growth 5YN/A